Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Advanced HCC: New systemic treatment options

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 398

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

Prof Hesham El-Ghazaly speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about novel systemic treatment options for hepatocellular carcinoma (HCC).

Prof El-Ghazaly highlights the prevalence of HCC as the most common cancer in Egypt - with Egypt having the highest incidence worldwide.

Prof El-Ghazaly believes HCC treatment should have a curative intent, which includes liver transplant, radiofrequency ablation and resection.
The addition of systemic treatment is particularly important to achieve a positive outcome in some patients - which is considered as an unmet need.

He also describes the emergence of additional treatments over the past two years, which include the combination of local treatments with sorafenib and immunotherapy.

For the future treatment of HCC, Prof El-Ghazaly believes a multi-disciplinary approach is needed, along with improvements in research activity.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation